Bone is Not Alone: the Effects of Skeletal Muscle Dysfunction in Chronic Kidney Disease

Keith G. Avin, Ranjani Moorthi

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Chronic kidney disease (CKD) is associated with a decline in muscle mass, strength, and function, collectively called “sarcopenia.” Sarcopenia is associated with hospitalizations and mortality in CKD and is therefore important to understand and characterize. While the focus of skeletal health in CKD has traditionally focused on bone and mineral aberrations, it is now recognized that sarcopenia must also play a role in poor musculoskeletal health in this population. In this paper, we present an overview of skeletal muscle changes in CKD, including defects in skeletal muscle catabolism and anabolism in uremic tissue. There are many gaps in knowledge in this field that should be the focus for future research to unravel pathogenesis and therapies for musculoskeletal health in CKD.

Original languageEnglish
Pages (from-to)173-179
Number of pages7
JournalCurrent Osteoporosis Reports
Volume13
Issue number3
DOIs
StatePublished - Jun 1 2015

Fingerprint

Chronic Renal Insufficiency
Sarcopenia
Skeletal Muscle
Bone and Bones
Health
Muscle Strength
Minerals
Hospitalization
Mortality
Population
Therapeutics

Keywords

  • Atrophy
  • Myogenesis
  • Myostatin
  • Sarcopenia
  • Skeletal muscle

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Bone is Not Alone : the Effects of Skeletal Muscle Dysfunction in Chronic Kidney Disease. / Avin, Keith G.; Moorthi, Ranjani.

In: Current Osteoporosis Reports, Vol. 13, No. 3, 01.06.2015, p. 173-179.

Research output: Contribution to journalArticle

@article{a258d8d3a2cb411c81ac2f45b25f647b,
title = "Bone is Not Alone: the Effects of Skeletal Muscle Dysfunction in Chronic Kidney Disease",
abstract = "Chronic kidney disease (CKD) is associated with a decline in muscle mass, strength, and function, collectively called “sarcopenia.” Sarcopenia is associated with hospitalizations and mortality in CKD and is therefore important to understand and characterize. While the focus of skeletal health in CKD has traditionally focused on bone and mineral aberrations, it is now recognized that sarcopenia must also play a role in poor musculoskeletal health in this population. In this paper, we present an overview of skeletal muscle changes in CKD, including defects in skeletal muscle catabolism and anabolism in uremic tissue. There are many gaps in knowledge in this field that should be the focus for future research to unravel pathogenesis and therapies for musculoskeletal health in CKD.",
keywords = "Atrophy, Myogenesis, Myostatin, Sarcopenia, Skeletal muscle",
author = "Avin, {Keith G.} and Ranjani Moorthi",
year = "2015",
month = "6",
day = "1",
doi = "10.1007/s11914-015-0261-4",
language = "English",
volume = "13",
pages = "173--179",
journal = "Current Alzheimer Research",
issn = "1546-9530",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Bone is Not Alone

T2 - the Effects of Skeletal Muscle Dysfunction in Chronic Kidney Disease

AU - Avin, Keith G.

AU - Moorthi, Ranjani

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Chronic kidney disease (CKD) is associated with a decline in muscle mass, strength, and function, collectively called “sarcopenia.” Sarcopenia is associated with hospitalizations and mortality in CKD and is therefore important to understand and characterize. While the focus of skeletal health in CKD has traditionally focused on bone and mineral aberrations, it is now recognized that sarcopenia must also play a role in poor musculoskeletal health in this population. In this paper, we present an overview of skeletal muscle changes in CKD, including defects in skeletal muscle catabolism and anabolism in uremic tissue. There are many gaps in knowledge in this field that should be the focus for future research to unravel pathogenesis and therapies for musculoskeletal health in CKD.

AB - Chronic kidney disease (CKD) is associated with a decline in muscle mass, strength, and function, collectively called “sarcopenia.” Sarcopenia is associated with hospitalizations and mortality in CKD and is therefore important to understand and characterize. While the focus of skeletal health in CKD has traditionally focused on bone and mineral aberrations, it is now recognized that sarcopenia must also play a role in poor musculoskeletal health in this population. In this paper, we present an overview of skeletal muscle changes in CKD, including defects in skeletal muscle catabolism and anabolism in uremic tissue. There are many gaps in knowledge in this field that should be the focus for future research to unravel pathogenesis and therapies for musculoskeletal health in CKD.

KW - Atrophy

KW - Myogenesis

KW - Myostatin

KW - Sarcopenia

KW - Skeletal muscle

UR - http://www.scopus.com/inward/record.url?scp=84939963456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939963456&partnerID=8YFLogxK

U2 - 10.1007/s11914-015-0261-4

DO - 10.1007/s11914-015-0261-4

M3 - Article

C2 - 25691218

AN - SCOPUS:84939963456

VL - 13

SP - 173

EP - 179

JO - Current Alzheimer Research

JF - Current Alzheimer Research

SN - 1546-9530

IS - 3

ER -